Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. is a phase 3, randomised interventional study registered as NCT06431633 by Fundación GECP, with a registry enrolment figure of 129 participants, started 2025-02-04 and due to reach its primary completion in 2031-11-30. Interventions recorded: Zimberelimab; Sacituzumab govitecan; Cisplatin; Carboplatin. Conditions listed: Lung Diseases; Carcinoma, Non-Small-Cell Lung; Resectable Lung Non-Small Cell Carcinoma. Primary outcome: Disease free survival. Lung eligibility wording from the registry: "Patients diagnosed of primary non-small cell lung cancer, histologically confirmed". Sites: Spain. No results are recorded here; the registry entry is the source.